{"transactions":[{"id":4618397,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:05:05.000Z","date":"2026-09-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":994,"price":156.22,"value":155282.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold."}],"balance_after":154728,"source":{"system":"sec-edgar","filing":"0001567160-26-000009","document":"wk-form4_1789506302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567160/000156716026000009/wk-form4_1789506302.xml","form_type":"4"}},{"id":4618396,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:05:05.000Z","date":"2026-09-11","kind":"grant","planned":false,"acquired":true,"shares":1842,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026."}],"balance_after":155722,"source":{"system":"sec-edgar","filing":"0001567160-26-000009","document":"wk-form4_1789506302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567160/000156716026000009/wk-form4_1789506302.xml","form_type":"4"}},{"id":4618395,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:05:05.000Z","date":"2026-09-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":3386,"price":156.22,"value":528960.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold."}],"balance_after":153880,"source":{"system":"sec-edgar","filing":"0001567160-26-000009","document":"wk-form4_1789506302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567160/000156716026000009/wk-form4_1789506302.xml","form_type":"4"}},{"id":4618394,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:05:05.000Z","date":"2026-09-11","kind":"grant","planned":false,"acquired":true,"shares":6275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":157266,"source":{"system":"sec-edgar","filing":"0001567160-26-000009","document":"wk-form4_1789506302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567160/000156716026000009/wk-form4_1789506302.xml","form_type":"4"}},{"id":902317,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-17T22:48:20.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":20142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030."}],"balance_after":20142,"derivative":{"underlying":"Common Stock","underlying_shares":20142},"source":{"system":"sec-edgar","filing":"0001567160-26-000007","document":"wk-form4_1771368497.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716026000007/wk-form4_1771368497.xml","form_type":"4"}},{"id":902316,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2026-02-17T22:48:20.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":114830,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":114830,"derivative":{"exercise_price":124.12,"expiration_date":"2036-02-13","underlying":"Common Stock","underlying_shares":114830},"source":{"system":"sec-edgar","filing":"0001567160-26-000007","document":"wk-form4_1771368497.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716026000007/wk-form4_1771368497.xml","form_type":"4"}},{"id":902315,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-17T22:48:20.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":false,"shares":2566,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 2,566 shares on February 13, 2024, vested as to 2,566 shares on February 13, 2025, vested as to 2,566 shares on February 13, 2026, and will vest as to 2,566 shares on February 13, 2027, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 2,566 shares on February 13, 2024, vested as to 2,566 shares on February 13, 2025, vested as to 2,566 shares on February 13, 2026, and will vest as to 2,566 shares on February 13, 2027, subject to the terms and conditions of the award."}],"balance_after":2566,"derivative":{"underlying":"Common Stock","underlying_shares":2566},"source":{"system":"sec-edgar","filing":"0001567160-26-000007","document":"wk-form4_1771368497.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716026000007/wk-form4_1771368497.xml","form_type":"4"}},{"id":902314,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-17T22:48:20.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":false,"shares":2241,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 2,241 shares on February 13, 2025, vested as to 2,241 shares on February 13, 2026, and will vest as to 2,242 shares on February 13, 2027, and 2,242 shares on February 13, 2028, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 2,241 shares on February 13, 2025, vested as to 2,241 shares on February 13, 2026, and will vest as to 2,242 shares on February 13, 2027, and 2,242 shares on February 13, 2028, subject to the terms and conditions of the award."}],"balance_after":4484,"derivative":{"underlying":"Common Stock","underlying_shares":2241},"source":{"system":"sec-edgar","filing":"0001567160-26-000007","document":"wk-form4_1771368497.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716026000007/wk-form4_1771368497.xml","form_type":"4"}},{"id":902313,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-17T22:48:20.000Z","date":"2026-02-12","kind":"exercise","planned":false,"acquired":false,"shares":4907,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 4,907 shares on February 12, 2026, and will vest as to 4,907 shares on February 12, 2027, 4,907 shares on February 12, 2028, and 4,907 shares on February 12, 2029, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 4,907 shares on February 12, 2026, and will vest as to 4,907 shares on February 12, 2027, 4,907 shares on February 12, 2028, and 4,907 shares on February 12, 2029, subject to the terms and conditions of the award."}],"balance_after":14721,"derivative":{"underlying":"Common Stock","underlying_shares":4907},"source":{"system":"sec-edgar","filing":"0001567160-26-000007","document":"wk-form4_1771368497.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716026000007/wk-form4_1771368497.xml","form_type":"4"}},{"id":902312,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:48:20.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":5378,"price":124.12,"value":667517.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."}],"balance_after":150815,"source":{"system":"sec-edgar","filing":"0001567160-26-000007","document":"wk-form4_1771368497.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716026000007/wk-form4_1771368497.xml","form_type":"4"}},{"id":902311,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:48:20.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":9968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award."}],"balance_after":156193,"source":{"system":"sec-edgar","filing":"0001567160-26-000007","document":"wk-form4_1771368497.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716026000007/wk-form4_1771368497.xml","form_type":"4"}},{"id":902310,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:48:20.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":1385,"price":124.12,"value":171906.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."}],"balance_after":146225,"source":{"system":"sec-edgar","filing":"0001567160-26-000007","document":"wk-form4_1771368497.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716026000007/wk-form4_1771368497.xml","form_type":"4"}},{"id":902309,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:48:20.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":true,"shares":2566,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":147610,"source":{"system":"sec-edgar","filing":"0001567160-26-000007","document":"wk-form4_1771368497.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716026000007/wk-form4_1771368497.xml","form_type":"4"}},{"id":902308,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:48:20.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":1210,"price":124.12,"value":150185.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."}],"balance_after":145044,"source":{"system":"sec-edgar","filing":"0001567160-26-000007","document":"wk-form4_1771368497.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716026000007/wk-form4_1771368497.xml","form_type":"4"}},{"id":902307,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:48:20.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":true,"shares":2241,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":146254,"source":{"system":"sec-edgar","filing":"0001567160-26-000007","document":"wk-form4_1771368497.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716026000007/wk-form4_1771368497.xml","form_type":"4"}},{"id":902306,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:48:20.000Z","date":"2026-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":2648,"price":123.1,"value":325968.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."}],"balance_after":144013,"source":{"system":"sec-edgar","filing":"0001567160-26-000007","document":"wk-form4_1771368497.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716026000007/wk-form4_1771368497.xml","form_type":"4"}},{"id":902305,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:48:20.000Z","date":"2026-02-12","kind":"exercise","planned":false,"acquired":true,"shares":4907,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":146661,"source":{"system":"sec-edgar","filing":"0001567160-26-000007","document":"wk-form4_1771368497.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716026000007/wk-form4_1771368497.xml","form_type":"4"}},{"id":922917,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-03T23:03:58.000Z","date":"2026-01-31","kind":"exercise","planned":false,"acquired":false,"shares":2927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,926 shares on January 31, 2023, vested as to 2,926 shares on January 31, 2024, vested as to 2,927 shares on January 31, 2025, and vested as to 2,927 shares on January 31, 2026, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,926 shares on January 31, 2023, vested as to 2,926 shares on January 31, 2024, vested as to 2,927 shares on January 31, 2025, and vested as to 2,927 shares on January 31, 2026, subject to the terms and conditions of the award."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2927},"source":{"system":"sec-edgar","filing":"0001567160-26-000005","document":"wk-form4_1770159832.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716026000005/wk-form4_1770159832.xml","form_type":"4"}},{"id":922916,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-03T23:03:58.000Z","date":"2026-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":1580,"price":136.06,"value":214974.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\"). No shares were sold."}],"balance_after":141754,"source":{"system":"sec-edgar","filing":"0001567160-26-000005","document":"wk-form4_1770159832.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716026000005/wk-form4_1770159832.xml","form_type":"4"}},{"id":922915,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-03T23:03:58.000Z","date":"2026-01-31","kind":"exercise","planned":false,"acquired":true,"shares":2927,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":143334,"source":{"system":"sec-edgar","filing":"0001567160-26-000005","document":"wk-form4_1770159832.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716026000005/wk-form4_1770159832.xml","form_type":"4"}},{"id":936067,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Incentive Stock Option","published_at":"2026-01-20T23:56:20.000Z","date":"2026-01-16","kind":"exercise","planned":true,"acquired":false,"shares":1812,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning on March 5, 2016. These options were due to expire on February 5, 2026."}],"balance_after":0,"derivative":{"exercise_price":35.99,"expiration_date":"2026-02-05","underlying":"Common Stock","underlying_shares":1812},"source":{"system":"sec-edgar","filing":"0001567160-26-000002","document":"wk-form4_1768953377.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716026000002/wk-form4_1768953377.xml","form_type":"4"}},{"id":936066,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2026-01-20T23:56:20.000Z","date":"2026-01-16","kind":"exercise","planned":true,"acquired":false,"shares":34588,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning on March 5, 2016. These options were due to expire on February 5, 2026."}],"balance_after":0,"derivative":{"exercise_price":35.99,"expiration_date":"2026-02-05","underlying":"Common Stock","underlying_shares":34588},"source":{"system":"sec-edgar","filing":"0001567160-26-000002","document":"wk-form4_1768953377.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716026000002/wk-form4_1768953377.xml","form_type":"4"}},{"id":936065,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-20T23:56:20.000Z","date":"2026-01-16","kind":"sale","planned":true,"acquired":false,"shares":1812,"price":132.7143,"value":240478.3116,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2025.  Additionally, Issuer policy\nrestricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.49 to $133.79. The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range"}],"balance_after":140407,"source":{"system":"sec-edgar","filing":"0001567160-26-000002","document":"wk-form4_1768953377.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716026000002/wk-form4_1768953377.xml","form_type":"4"}},{"id":936064,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-20T23:56:20.000Z","date":"2026-01-16","kind":"exercise","planned":true,"acquired":true,"shares":1812,"price":35.99,"value":65213.88,"ownership":{"direct":true},"balance_after":142219,"source":{"system":"sec-edgar","filing":"0001567160-26-000002","document":"wk-form4_1768953377.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716026000002/wk-form4_1768953377.xml","form_type":"4"}},{"id":936063,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-20T23:56:20.000Z","date":"2026-01-16","kind":"sale","planned":true,"acquired":false,"shares":34588,"price":132.7044,"value":4589979.7872,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2025.  Additionally, Issuer policy\nrestricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.42 to $133.98. The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range"}],"balance_after":140407,"source":{"system":"sec-edgar","filing":"0001567160-26-000002","document":"wk-form4_1768953377.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716026000002/wk-form4_1768953377.xml","form_type":"4"}},{"id":936062,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-20T23:56:20.000Z","date":"2026-01-16","kind":"exercise","planned":true,"acquired":true,"shares":34588,"price":35.99,"value":1244822.12,"ownership":{"direct":true},"balance_after":174995,"source":{"system":"sec-edgar","filing":"0001567160-26-000002","document":"wk-form4_1768953377.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716026000002/wk-form4_1768953377.xml","form_type":"4"}},{"id":1008808,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-11-05T01:18:14.000Z","date":"2025-11-01","kind":"exercise","planned":false,"acquired":false,"shares":613,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This RSU was granted to the Reporting Person on November 1, 2024.   In accordance with the terms of the RSU, the award vested as to 613 shares on November 1, 2025, and will vest as to 614 shares on\nNovember 1, 2026, 614 shares on November 1, 2027, and 614 shares on November 1, 2028, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This RSU was granted to the Reporting Person on November 1, 2024.   In accordance with the terms of the RSU, the award vested as to 613 shares on November 1, 2025, and will vest as to 614 shares on\nNovember 1, 2026, 614 shares on November 1, 2027, and 614 shares on November 1, 2028, subject to the terms and conditions of the award."}],"balance_after":1842,"derivative":{"underlying":"Common Stock","underlying_shares":613},"source":{"system":"sec-edgar","filing":"0001567160-25-000008","document":"wk-form4_1762305492.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716025000008/wk-form4_1762305492.xml","form_type":"4"}},{"id":1008807,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-05T01:18:14.000Z","date":"2025-11-04","kind":"sale","planned":false,"acquired":false,"shares":300,"price":141.97,"value":42591.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":140407,"source":{"system":"sec-edgar","filing":"0001567160-25-000008","document":"wk-form4_1762305492.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716025000008/wk-form4_1762305492.xml","form_type":"4"}},{"id":1008806,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-05T01:18:14.000Z","date":"2025-11-01","kind":"exercise","planned":false,"acquired":true,"shares":613,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 200 shares purchased on February 28, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":140720,"source":{"system":"sec-edgar","filing":"0001567160-25-000008","document":"wk-form4_1762305492.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000156716025000008/wk-form4_1762305492.xml","form_type":"4"}},{"id":1268310,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-14T23:20:05.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":false,"shares":2241,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 2,241 shares on February 13, 2025, and will vest as to 2,241 shares on February 13, 2026, 2,242 shares on February 13, 2027, and 2,242 shares on February 13, 2028, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 2,241 shares on February 13, 2025, and will vest as to 2,241 shares on February 13, 2026, 2,242 shares on February 13, 2027, and 2,242 shares on February 13, 2028, subject to the terms and conditions of the award."}],"balance_after":6725,"derivative":{"underlying":"Common Stock","underlying_shares":2241},"source":{"system":"sec-edgar","filing":"0000914475-25-000063","document":"wk-form4_1739575198.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000063/wk-form4_1739575198.xml","form_type":"4"}},{"id":1268309,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-14T23:20:05.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":false,"shares":2566,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 2,566 shares on February 13, 2024, vested as to 2,566 shares on February 13, 2025, and will vest as to 2,566 shares on February 13, 2026, and  2,566 shares on February 13, 2027, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 2,566 shares on February 13, 2024, vested as to 2,566 shares on February 13, 2025, and will vest as to 2,566 shares on February 13, 2026, and  2,566 shares on February 13, 2027, subject to the terms and conditions of the award."}],"balance_after":5132,"derivative":{"underlying":"Common Stock","underlying_shares":2566},"source":{"system":"sec-edgar","filing":"0000914475-25-000063","document":"wk-form4_1739575198.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000063/wk-form4_1739575198.xml","form_type":"4"}},{"id":1268308,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-14T23:20:05.000Z","date":"2025-02-12","kind":"grant","planned":true,"acquired":true,"shares":19628,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029."}],"balance_after":19628,"derivative":{"underlying":"Common Stock","underlying_shares":19628},"source":{"system":"sec-edgar","filing":"0000914475-25-000063","document":"wk-form4_1739575198.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000063/wk-form4_1739575198.xml","form_type":"4"}},{"id":1268307,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2025-02-14T23:20:05.000Z","date":"2025-02-12","kind":"grant","planned":true,"acquired":true,"shares":104736,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":104736,"derivative":{"exercise_price":117.18,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":104736},"source":{"system":"sec-edgar","filing":"0000914475-25-000063","document":"wk-form4_1739575198.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000063/wk-form4_1739575198.xml","form_type":"4"}},{"id":1268306,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:20:05.000Z","date":"2025-02-13","kind":"sale","planned":true,"acquired":false,"shares":1206,"price":116.8606,"value":140933.8836,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.04 to $117.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":139907,"source":{"system":"sec-edgar","filing":"0000914475-25-000063","document":"wk-form4_1739575198.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000063/wk-form4_1739575198.xml","form_type":"4"}},{"id":1268305,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:20:05.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":true,"shares":2241,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":141113,"source":{"system":"sec-edgar","filing":"0000914475-25-000063","document":"wk-form4_1739575198.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000063/wk-form4_1739575198.xml","form_type":"4"}},{"id":1268304,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:20:05.000Z","date":"2025-02-13","kind":"sale","planned":true,"acquired":false,"shares":1352,"price":116.8448,"value":157974.1696,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.02 to $118.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":138872,"source":{"system":"sec-edgar","filing":"0000914475-25-000063","document":"wk-form4_1739575198.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000063/wk-form4_1739575198.xml","form_type":"4"}},{"id":1268303,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:20:05.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":true,"shares":2566,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":140224,"source":{"system":"sec-edgar","filing":"0000914475-25-000063","document":"wk-form4_1739575198.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000063/wk-form4_1739575198.xml","form_type":"4"}},{"id":1272428,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-12T23:48:10.000Z","date":"2025-02-08","kind":"exercise","planned":true,"acquired":false,"shares":1860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This RSU was granted to the Reporting Person on February 8, 2021.  In accordance with the terms of the RSU, the award vested as to 1,859 shares on February 8, 2022, vested as to 1,860 shares on February 8, 2023, vested as to 1,860 shares on February 8, 2024, and vested as to 1,860 shares on February 8, 2025, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This RSU was granted to the Reporting Person on February 8, 2021.  In accordance with the terms of the RSU, the award vested as to 1,859 shares on February 8, 2022, vested as to 1,860 shares on February 8, 2023, vested as to 1,860 shares on February 8, 2024, and vested as to 1,860 shares on February 8, 2025, subject to the terms and conditions of the award."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1860},"source":{"system":"sec-edgar","filing":"0000914475-25-000049","document":"wk-form4_1739404081.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000049/wk-form4_1739404081.xml","form_type":"4"}},{"id":1272427,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-12T23:48:10.000Z","date":"2025-02-10","kind":"sale","planned":true,"acquired":false,"shares":980,"price":118.3881,"value":116020.338,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.08 to $123.57. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":137658,"source":{"system":"sec-edgar","filing":"0000914475-25-000049","document":"wk-form4_1739404081.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000049/wk-form4_1739404081.xml","form_type":"4"}},{"id":1272426,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-12T23:48:10.000Z","date":"2025-02-08","kind":"exercise","planned":true,"acquired":true,"shares":1860,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":138638,"source":{"system":"sec-edgar","filing":"0000914475-25-000049","document":"wk-form4_1739404081.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000049/wk-form4_1739404081.xml","form_type":"4"}},{"id":1285986,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-04T22:47:13.000Z","date":"2025-01-31","kind":"exercise","planned":true,"acquired":false,"shares":2927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,926 shares on January 31, 2023, vested as to 2,926 shares on January 31, 2024, vested as to 2,927 shares on January 31, 2025, and will vest as to 2,927 shares on January 31, 2026, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,926 shares on January 31, 2023, vested as to 2,926 shares on January 31, 2024, vested as to 2,927 shares on January 31, 2025, and will vest as to 2,927 shares on January 31, 2026, subject to the terms and conditions of the award."}],"balance_after":2927,"derivative":{"underlying":"Common Stock","underlying_shares":2927},"source":{"system":"sec-edgar","filing":"0000914475-25-000025","document":"wk-form4_1738709227.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000025/wk-form4_1738709227.xml","form_type":"4"}},{"id":1285985,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-04T22:47:13.000Z","date":"2025-01-31","kind":"sale","planned":true,"acquired":false,"shares":1541,"price":152.8731,"value":235577.4471,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.94 to $153.59. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":136778,"source":{"system":"sec-edgar","filing":"0000914475-25-000025","document":"wk-form4_1738709227.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000025/wk-form4_1738709227.xml","form_type":"4"}},{"id":1285984,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-04T22:47:13.000Z","date":"2025-01-31","kind":"exercise","planned":true,"acquired":true,"shares":2927,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":138319,"source":{"system":"sec-edgar","filing":"0000914475-25-000025","document":"wk-form4_1738709227.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000025/wk-form4_1738709227.xml","form_type":"4"}},{"id":1300917,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2025-01-17T21:32:00.000Z","date":"2025-01-15","kind":"exercise","planned":true,"acquired":false,"shares":60188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted February 3, 2015 and vested in 48 equal monthly installments beginning on March 3, 2015. These options  were due to expire on February 3, 2025."}],"balance_after":0,"derivative":{"exercise_price":32.99,"expiration_date":"2025-02-03","underlying":"Common Stock","underlying_shares":60188},"source":{"system":"sec-edgar","filing":"0000914475-25-000004","document":"wk-form4_1737149514.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000004/wk-form4_1737149514.xml","form_type":"4"}},{"id":1300916,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Incentive Stock Option","published_at":"2025-01-17T21:32:00.000Z","date":"2025-01-15","kind":"exercise","planned":true,"acquired":false,"shares":4812,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted February 3, 2015 and vested in 48 equal monthly installments beginning on March 3, 2015. These options  were due to expire on February 3, 2025."}],"balance_after":0,"derivative":{"exercise_price":32.99,"expiration_date":"2025-02-03","underlying":"Common Stock","underlying_shares":4812},"source":{"system":"sec-edgar","filing":"0000914475-25-000004","document":"wk-form4_1737149514.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000004/wk-form4_1737149514.xml","form_type":"4"}},{"id":1300915,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-17T21:32:00.000Z","date":"2025-01-15","kind":"sale","planned":true,"acquired":false,"shares":60188,"price":141.5009,"value":8516656.1692,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.53 to $142.62. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes an aggregate of 226 shares purchased on February 29, 2024, from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":135392,"source":{"system":"sec-edgar","filing":"0000914475-25-000004","document":"wk-form4_1737149514.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000004/wk-form4_1737149514.xml","form_type":"4"}},{"id":1300914,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-17T21:32:00.000Z","date":"2025-01-15","kind":"exercise","planned":true,"acquired":true,"shares":60188,"price":32.99,"value":1985602.12,"ownership":{"direct":true},"balance_after":195580,"source":{"system":"sec-edgar","filing":"0000914475-25-000004","document":"wk-form4_1737149514.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000004/wk-form4_1737149514.xml","form_type":"4"}},{"id":1300913,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-17T21:32:00.000Z","date":"2025-01-15","kind":"sale","planned":true,"acquired":false,"shares":4812,"price":141.4991,"value":680893.6692,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.53 to $142.62. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":135392,"source":{"system":"sec-edgar","filing":"0000914475-25-000004","document":"wk-form4_1737149514.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000004/wk-form4_1737149514.xml","form_type":"4"}},{"id":1300912,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-17T21:32:00.000Z","date":"2025-01-15","kind":"exercise","planned":true,"acquired":true,"shares":4812,"price":32.99,"value":158747.88,"ownership":{"direct":true},"balance_after":140204,"source":{"system":"sec-edgar","filing":"0000914475-25-000004","document":"wk-form4_1737149514.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000004/wk-form4_1737149514.xml","form_type":"4"}},{"id":1378463,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2024-11-01T23:52:05.000Z","date":"2024-11-01","kind":"grant","planned":false,"acquired":true,"shares":13344,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on December 1,  2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":13344,"derivative":{"exercise_price":122.21,"expiration_date":"2034-11-01","underlying":"Common Stock","underlying_shares":13344},"source":{"system":"sec-edgar","filing":"0000914475-24-000216","document":"wk-form4_1730505118.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000216/wk-form4_1730505118.xml","form_type":"4"}},{"id":1378462,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-11-01T23:52:05.000Z","date":"2024-11-01","kind":"grant","planned":false,"acquired":true,"shares":2455,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of November 1, 2025, November 1, 2026, November 1, 2027, and November 1, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of November 1, 2025, November 1, 2026, November 1, 2027, and November 1, 2028."}],"balance_after":2455,"derivative":{"underlying":"Common Stock","underlying_shares":2455},"source":{"system":"sec-edgar","filing":"0000914475-24-000216","document":"wk-form4_1730505118.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000216/wk-form4_1730505118.xml","form_type":"4"}},{"id":1641726,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Restricted Stock Unit","published_at":"2024-02-15T22:40:20.000Z","date":"2024-02-13","kind":"grant","planned":true,"acquired":true,"shares":8966,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028."}],"balance_after":8966,"derivative":{"underlying":"Common Stock","underlying_shares":8966},"source":{"system":"sec-edgar","filing":"0000914475-24-000072","document":"wk-form4_1708036809.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000072/wk-form4_1708036809.xml","form_type":"4"}},{"id":1641725,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Stock Option","published_at":"2024-02-15T22:40:20.000Z","date":"2024-02-13","kind":"grant","planned":true,"acquired":true,"shares":45058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":45058,"derivative":{"exercise_price":133.84,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":45058},"source":{"system":"sec-edgar","filing":"0000914475-24-000072","document":"wk-form4_1708036809.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000072/wk-form4_1708036809.xml","form_type":"4"}},{"id":1641724,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2024-02-15T22:40:20.000Z","date":"2024-02-13","kind":"sale","planned":true,"acquired":false,"shares":1352,"price":132.8947,"value":179673.6344,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,352 shares of common stock issued upon vesting of 2,566 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,214) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.98 to $133.96. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":135166,"source":{"system":"sec-edgar","filing":"0000914475-24-000072","document":"wk-form4_1708036809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000072/wk-form4_1708036809.xml","form_type":"4"}},{"id":1654154,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2024-02-09T00:17:25.000Z","date":"2024-02-08","kind":"sale","planned":true,"acquired":false,"shares":980,"price":134.2032,"value":131519.136,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":133952,"source":{"system":"sec-edgar","filing":"0000914475-24-000045","document":"wk-form4_1707437835.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000045/wk-form4_1707437835.xml","form_type":"4"}},{"id":1654153,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2024-02-09T00:17:25.000Z","date":"2024-02-06","kind":"sale","planned":true,"acquired":false,"shares":1600,"price":142.2013,"value":227522.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,600 shares of common stock issued upon vesting of 3,037 restricted stock units on February  6, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,437) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.07 to $142.95. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":133072,"source":{"system":"sec-edgar","filing":"0000914475-24-000045","document":"wk-form4_1707437835.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000045/wk-form4_1707437835.xml","form_type":"4"}},{"id":1662748,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2024-02-03T00:17:08.000Z","date":"2024-01-31","kind":"sale","planned":true,"acquired":false,"shares":1541,"price":140.696,"value":216812.536,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,541 shares of common stock issued upon vesting of 2,926 restricted stock units on January 31, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,385) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.74 to $141.98. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":131635,"source":{"system":"sec-edgar","filing":"0000914475-24-000027","document":"wk-form4_1706919417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000027/wk-form4_1706919417.xml","form_type":"4"}},{"id":1689192,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Incentive Stock Option","published_at":"2024-01-04T23:32:49.000Z","date":"2024-01-02","kind":"exercise","planned":true,"acquired":false,"shares":6116,"price":19.59,"value":119812.44,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted January 16, 2014 and vested in 48 equal monthly  installments beginning February 16, 2014.  These options will expire ten years from the date of grant on January 16, 2024."}],"balance_after":0,"derivative":{"exercise_price":19.59,"expiration_date":"2024-01-16","underlying":"Common Stock","underlying_shares":6116},"source":{"system":"sec-edgar","filing":"0000914475-24-000007","document":"wk-form4_1704411157.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000007/wk-form4_1704411157.xml","form_type":"4"}},{"id":1689191,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Non-Qualified Stock Option","published_at":"2024-01-04T23:32:49.000Z","date":"2024-01-02","kind":"exercise","planned":true,"acquired":false,"shares":68884,"price":19.59,"value":1349437.56,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted January 16, 2014 and vested in 48 equal monthly  installments beginning February 16, 2014.  These options will expire ten years from the date of grant on January 16, 2024."}],"balance_after":0,"derivative":{"exercise_price":19.59,"expiration_date":"2024-01-16","underlying":"Common Stock","underlying_shares":68884},"source":{"system":"sec-edgar","filing":"0000914475-24-000007","document":"wk-form4_1704411157.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000007/wk-form4_1704411157.xml","form_type":"4"}},{"id":1689190,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2024-01-04T23:32:49.000Z","date":"2024-01-02","kind":"sale","planned":true,"acquired":false,"shares":6116,"price":131.4429,"value":803904.7764,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $130.76 to $133.27. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":130250,"source":{"system":"sec-edgar","filing":"0000914475-24-000007","document":"wk-form4_1704411157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000007/wk-form4_1704411157.xml","form_type":"4"}},{"id":1689189,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2024-01-04T23:32:49.000Z","date":"2024-01-02","kind":"exercise","planned":true,"acquired":true,"shares":6116,"price":19.59,"value":119812.44,"ownership":{"direct":true},"balance_after":136366,"source":{"system":"sec-edgar","filing":"0000914475-24-000007","document":"wk-form4_1704411157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000007/wk-form4_1704411157.xml","form_type":"4"}},{"id":1689188,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2024-01-04T23:32:49.000Z","date":"2024-01-02","kind":"sale","planned":true,"acquired":false,"shares":68884,"price":131.4716,"value":9056289.6944,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $130.76 to $133.33. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":130250,"source":{"system":"sec-edgar","filing":"0000914475-24-000007","document":"wk-form4_1704411157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000007/wk-form4_1704411157.xml","form_type":"4"}},{"id":1689187,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2024-01-04T23:32:49.000Z","date":"2024-01-02","kind":"exercise","planned":true,"acquired":true,"shares":68884,"price":19.59,"value":1349437.56,"ownership":{"direct":true},"balance_after":199134,"source":{"system":"sec-edgar","filing":"0000914475-24-000007","document":"wk-form4_1704411157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000007/wk-form4_1704411157.xml","form_type":"4"}},{"id":1799013,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2023-08-24T00:05:58.000Z","date":"2023-08-21","kind":"sale","planned":true,"acquired":false,"shares":2132,"price":107.4075,"value":228992.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,132 shares of common stock issued upon vesting of 4,050 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,918) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.05 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes an aggregate of 236 shares purchased on February 28, 2023 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":130250,"source":{"system":"sec-edgar","filing":"0001209191-23-047135","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123047135/doc4.xml","form_type":"4"}},{"id":2014205,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Restricted Stock Unit","published_at":"2023-02-16T00:10:56.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":10264,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027."}],"balance_after":10264,"derivative":{"underlying":"Common Stock","underlying_shares":10264},"source":{"system":"sec-edgar","filing":"0001209191-23-009884","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123009884/doc4.xml","form_type":"4"}},{"id":2014204,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Stock Option","published_at":"2023-02-16T00:10:56.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":63789,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":63789,"derivative":{"exercise_price":103.52,"expiration_date":"2033-02-13","underlying":"Common Stock","underlying_shares":63789},"source":{"system":"sec-edgar","filing":"0001209191-23-009884","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123009884/doc4.xml","form_type":"4"}},{"id":2026994,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2023-02-09T00:25:33.000Z","date":"2023-02-08","kind":"sale","acquired":false,"shares":980,"price":103.9898,"value":101910.004,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8, 2023 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.53 to $105.71. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":128096,"source":{"system":"sec-edgar","filing":"0001209191-23-007910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007910/doc4.xml","form_type":"4"}},{"id":2026993,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2023-02-09T00:25:33.000Z","date":"2023-02-07","kind":"sale","acquired":false,"shares":12801,"price":102.4114,"value":1310968.3314,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Sale of 12,801 shares of common stock issued upon vesting of 24,298 performance restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (11,497) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"kind","element":"transactionCoding","label":"F6","text":"The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on February 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.08 to $104.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":127216,"source":{"system":"sec-edgar","filing":"0001209191-23-007910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007910/doc4.xml","form_type":"4"}},{"id":2026992,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2023-02-09T00:25:33.000Z","date":"2023-02-07","kind":"sale","acquired":false,"shares":1623,"price":102.2884,"value":166014.0732,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 1,623 shares of common stock issued upon vesting of 3,085 restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,462) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.42 to $103.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":115719,"source":{"system":"sec-edgar","filing":"0001209191-23-007910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007910/doc4.xml","form_type":"4"}},{"id":2026991,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2023-02-09T00:25:33.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":1600,"price":105.6422,"value":169027.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,600 shares of common stock issued upon vesting of 3,037 restricted stock units on February 6, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,437) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.01 to $106.99. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":114257,"source":{"system":"sec-edgar","filing":"0001209191-23-007910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007910/doc4.xml","form_type":"4"}},{"id":2037153,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2023-02-02T22:15:33.000Z","date":"2023-01-31","kind":"sale","acquired":false,"shares":1541,"price":109.9847,"value":169486.4227,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,541 shares of common stock issued upon vesting of 2,926 restricted stock units on January 31, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,385) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes an aggregate of 262 shares purchased on February 28, 2022 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":112820,"source":{"system":"sec-edgar","filing":"0001209191-23-006275","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123006275/doc4.xml","form_type":"4"}},{"id":2406971,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2022-02-09T23:58:10.000Z","date":"2022-02-08","kind":"sale","acquired":false,"shares":980,"price":79.672,"value":78078.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"Sale of 980 shares of common stock issued upon vesting of 1,859 restricted stock units on February 8, 2022 to cover payroll and withholding taxes, with the balance of the shares (879) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.08 to $80.21. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":111173,"source":{"system":"sec-edgar","filing":"0001209191-22-008207","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122008207/doc4.xml","form_type":"4"}},{"id":2406970,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2022-02-09T23:58:10.000Z","date":"2022-02-07","kind":"sale","acquired":false,"shares":1600,"price":80.7656,"value":129224.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Sale of 1,600 shares of common stock issued upon vesting of 3,037 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (1,437) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.65 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":110294,"source":{"system":"sec-edgar","filing":"0001209191-22-008207","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122008207/doc4.xml","form_type":"4"}},{"id":2406969,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2022-02-09T23:58:10.000Z","date":"2022-02-07","kind":"sale","acquired":false,"shares":1623,"price":80.7791,"value":131104.4793,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Sale of 1,623 shares of common stock issued upon vesting of 3,085 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (1,462) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.77 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":108857,"source":{"system":"sec-edgar","filing":"0001209191-22-008207","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122008207/doc4.xml","form_type":"4"}},{"id":2406968,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2022-02-09T23:58:10.000Z","date":"2022-02-07","kind":"sale","acquired":false,"shares":1974,"price":80.8002,"value":159499.5948,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 1,974 shares of common stock issued upon vesting of 3,750 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (1,776) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.72 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":107395,"source":{"system":"sec-edgar","filing":"0001209191-22-008207","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122008207/doc4.xml","form_type":"4"}},{"id":2406967,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2022-02-09T23:58:10.000Z","date":"2022-02-07","kind":"sale","acquired":false,"shares":703,"price":80.683,"value":56720.149,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 703 shares of common stock issued upon vesting of 1,338 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (635) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.78 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":105619,"source":{"system":"sec-edgar","filing":"0001209191-22-008207","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122008207/doc4.xml","form_type":"4"}},{"id":2417567,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Restricted Stock Unit","published_at":"2022-02-03T01:02:57.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":11706,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026."}],"balance_after":11706,"derivative":{"underlying":"Common Stock","underlying_shares":11706},"source":{"system":"sec-edgar","filing":"0001209191-22-006587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122006587/doc4.xml","form_type":"4"}},{"id":2417566,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Stock Option","published_at":"2022-02-03T01:02:57.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":79720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":79720,"derivative":{"exercise_price":79.02,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":79720},"source":{"system":"sec-edgar","filing":"0001209191-22-006587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122006587/doc4.xml","form_type":"4"}},{"id":2440673,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Non-Qualified Stock Option","published_at":"2022-01-07T23:04:58.000Z","date":"2022-01-05","kind":"exercise","acquired":false,"shares":28266,"price":8.66,"value":244783.56,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted January 12, 2012 and vested monthly over four years."}],"balance_after":0,"derivative":{"exercise_price":8.66,"expiration_date":"2022-01-12","underlying":"Common Stock","underlying_shares":28266},"source":{"system":"sec-edgar","filing":"0001209191-22-002529","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122002529/doc4.xml","form_type":"4"}},{"id":2440672,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2022-01-07T23:04:58.000Z","date":"2022-01-05","kind":"sale","acquired":false,"shares":28266,"price":85.5003,"value":2416751.4798,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $83.11 to $87.76. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes an aggregate of 216 shares purchased on February 26, 2021 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":104984,"source":{"system":"sec-edgar","filing":"0001209191-22-002529","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122002529/doc4.xml","form_type":"4"}},{"id":2440671,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2022-01-07T23:04:58.000Z","date":"2022-01-05","kind":"exercise","acquired":true,"shares":28266,"price":8.66,"value":244783.56,"ownership":{"direct":true},"balance_after":133250,"source":{"system":"sec-edgar","filing":"0001209191-22-002529","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122002529/doc4.xml","form_type":"4"}},{"id":2769846,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Stock Option","published_at":"2021-03-29T10:15:51.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":49049,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":49049,"derivative":{"exercise_price":117.63,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":49049},"source":{"system":"sec-edgar","filing":"0001209191-21-023376","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121023376/doc4a.xml","form_type":"4/A","original_submission_date":"2021-02-09"}},{"id":2872983,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Restricted Stock Unit","published_at":"2021-02-10T02:42:22.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":7439,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F12","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F13","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025."}],"balance_after":7439,"derivative":{"underlying":"Common Stock","underlying_shares":7439},"source":{"system":"sec-edgar","filing":"0001209191-21-009134","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009134/doc4.xml","form_type":"4"}},{"id":2872982,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Stock Option","published_at":"2021-02-10T02:42:22.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":44632,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":44632,"derivative":{"exercise_price":117.63,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":44632},"source":{"system":"sec-edgar","filing":"0001209191-21-009134","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009134/doc4.xml","form_type":"4"}},{"id":2872981,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2021-02-10T02:42:22.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":1623,"price":116.834,"value":189621.582,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"Sale of 1,623 shares of common stock issued upon vesting of 3,085 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,462) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.99 to $117.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":104768,"source":{"system":"sec-edgar","filing":"0001209191-21-009134","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009134/doc4.xml","form_type":"4"}},{"id":2872980,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2021-02-10T02:42:22.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":1000,"price":116.8259,"value":116825.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Sale of 1,000 shares of common stock issued upon vesting of 1,900 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (900) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $117.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":103306,"source":{"system":"sec-edgar","filing":"0001209191-21-009134","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009134/doc4.xml","form_type":"4"}},{"id":2872979,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2021-02-10T02:42:22.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":1070,"price":116.8882,"value":125070.374,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Sale of 1,070 shares of common stock issued upon vesting of 3,037 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,967) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.06 to $117.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":102406,"source":{"system":"sec-edgar","filing":"0001209191-21-009134","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009134/doc4.xml","form_type":"4"}},{"id":2872978,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2021-02-10T02:42:22.000Z","date":"2021-02-05","kind":"sale","acquired":false,"shares":1974,"price":114.0866,"value":225206.9484,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 1,974 shares of common stock issued upon vesting of 3,750 restricted stock units on February 5, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,776) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.65 to $116.43. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":100439,"source":{"system":"sec-edgar","filing":"0001209191-21-009134","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009134/doc4.xml","form_type":"4"}},{"id":2872977,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2021-02-10T02:42:22.000Z","date":"2021-02-05","kind":"sale","acquired":false,"shares":703,"price":113.7658,"value":79977.3574,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 703 shares of common stock issued upon vesting of 1,338 restricted stock units on February 5, 2021 to cover payroll and withholding taxes, with the balance of the shares (635) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.51 to $116.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":98663,"source":{"system":"sec-edgar","filing":"0001209191-21-009134","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009134/doc4.xml","form_type":"4"}},{"id":2980245,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2020-11-16T23:11:48.000Z","date":"2020-11-12","kind":"sale","acquired":false,"shares":2257,"price":90.7268,"value":204770.3876,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,257 shares of common stock issued upon vesting of 4,288 performance restricted stock units to cover withholding taxes, with the balance of the shares (2,031) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $88.93 to $92.23. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":98028,"source":{"system":"sec-edgar","filing":"0001209191-20-058543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120058543/doc4.xml","form_type":"4"}},{"id":3065173,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2020-08-07T23:24:31.000Z","date":"2020-08-05","kind":"sale","acquired":false,"shares":2257,"price":118.8682,"value":268285.5274,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,257 shares of common stock issued upon vesting of 4,287 performance restricted stock units to cover withholding\ntaxes, with the balance of the shares (2,030) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a\nbroker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction\ndate in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan\nsubsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $118.21 to $120.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":95997,"source":{"system":"sec-edgar","filing":"0001209191-20-045749","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120045749/doc4.xml","form_type":"4"}},{"id":3168575,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2020-04-29T00:40:17.000Z","date":"2020-04-24","kind":"sale","acquired":false,"shares":1934,"price":99.4709,"value":192376.7206,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,934 shares of common stock issued upon vesting of 3,675 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (1,741) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.65 to $101.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 251 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 28, 2020."}],"balance_after":93967,"source":{"system":"sec-edgar","filing":"0001209191-20-026066","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120026066/doc4.xml","form_type":"4"}},{"id":3280431,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2020-02-12T00:13:11.000Z","date":"2020-02-07","kind":"sale","acquired":false,"shares":1623,"price":103.3335,"value":167710.2705,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,623 shares of common stock issued upon vesting of 3,084 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,461) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.22 to $104.09. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":91975,"source":{"system":"sec-edgar","filing":"0001209191-20-008491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120008491/doc4.xml","form_type":"4"}},{"id":3285302,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Restricted Stock Unit","published_at":"2020-02-07T23:54:24.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":12148,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F11","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024."}],"balance_after":12148,"derivative":{"underlying":"Common Stock","underlying_shares":12148},"source":{"system":"sec-edgar","filing":"0001209191-20-007695","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007695/doc4.xml","form_type":"4"}},{"id":3285301,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Stock Option","published_at":"2020-02-07T23:54:24.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":76683,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":76683,"derivative":{"exercise_price":102.9,"expiration_date":"2030-02-06","underlying":"Common Stock","underlying_shares":76683},"source":{"system":"sec-edgar","filing":"0001209191-20-007695","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007695/doc4.xml","form_type":"4"}},{"id":3285300,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2020-02-07T23:54:24.000Z","date":"2020-02-06","kind":"sale","acquired":false,"shares":1000,"price":101.413,"value":101413.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Sale of 1,000 shares of common stock issued upon vesting of 1,900 restricted stock units on February 6, 2020 to cover payroll and withholding taxes, with the balance of the shares (900) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $99.73 to $103.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":90514,"source":{"system":"sec-edgar","filing":"0001209191-20-007695","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007695/doc4.xml","form_type":"4"}},{"id":3285299,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2020-02-07T23:54:24.000Z","date":"2020-02-05","kind":"sale","acquired":false,"shares":1974,"price":103.0812,"value":203482.2888,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Sale of 1,974 shares of common stock issued upon vesting of 3,750 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,776) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.86 to $105.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":89614,"source":{"system":"sec-edgar","filing":"0001209191-20-007695","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007695/doc4.xml","form_type":"4"}},{"id":3285298,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2020-02-07T23:54:24.000Z","date":"2020-02-05","kind":"sale","acquired":false,"shares":703,"price":103.0347,"value":72433.3941,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Sale of 703 shares of common stock issued upon vesting of 1,337 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (634) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.90 to $104.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":87838,"source":{"system":"sec-edgar","filing":"0001209191-20-007695","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007695/doc4.xml","form_type":"4"}},{"id":3285297,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Common Stock","published_at":"2020-02-07T23:54:24.000Z","date":"2020-02-05","kind":"sale","acquired":false,"shares":1013,"price":103.0072,"value":104346.2936,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,013 shares of common stock issued upon vesting of 1,925 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (912) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.16 to $105.09. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes a total of 459 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan, consisting of 312 shares on February 28, 2019 and 147 shares on August 30, 2019."}],"balance_after":87204,"source":{"system":"sec-edgar","filing":"0001209191-20-007695","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007695/doc4.xml","form_type":"4"}},{"id":3669078,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Development Off"}}],"security":"Restricted Stock Unit","published_at":"2019-02-08T22:07:23.000Z","date":"2019-02-07","kind":"grant","acquired":true,"shares":12339,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 7, 2020, February 7, 2021, February 7, 2022, and February 7, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 7, 2020, February 7, 2021, February 7, 2022, and February 7, 2023."}],"balance_after":12339,"derivative":{"underlying":"Common Stock","underlying_shares":12339},"source":{"system":"sec-edgar","filing":"0001209191-19-008630","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119008630/doc4.xml","form_type":"4"}}],"next_cursor":"2019-02-08T22:07:23.000000Z,3669078"}